These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 33332056)

  • 1. [Covid-19 reinfections: what is the clinical relevance?].
    Wiersinga WJ; de Bree GJ
    Ned Tijdschr Geneeskd; 2020 Dec; 164():. PubMed ID: 33332056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components.
    Priyanka ; Choudhary OP; Singh I
    Travel Med Infect Dis; 2021; 39():101911. PubMed ID: 33186686
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunity to glycan α-Gal and possibilities for the control of COVID-19.
    la Fuente J; Gortázar C; Cabezas-Cruz A
    Immunotherapy; 2021 Feb; 13(3):185-188. PubMed ID: 33307805
    [No Abstract]   [Full Text] [Related]  

  • 4. Reinfection with SARS-CoV-2: Discrete SIR (Susceptible, Infected, Recovered) Modeling Using Empirical Infection Data.
    McMahon A; Robb NC
    JMIR Public Health Surveill; 2020 Nov; 6(4):e21168. PubMed ID: 33052872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 reinfection and implications for vaccine development.
    Nainu F; Abidin RS; Bahar MA; Frediansyah A; Emran TB; Rabaan AA; Dhama K; Harapan H
    Hum Vaccin Immunother; 2020 Dec; 16(12):3061-3073. PubMed ID: 33393854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(25):e100. PubMed ID: 34910868
    [No Abstract]   [Full Text] [Related]  

  • 7. SARS-CoV-2 reinfections in a US university setting, Fall 2020 to Spring 2021.
    Rosenberg M; Chen C; Golzarri-Arroyo L; Carroll A; Menachemi N; Ludema C
    BMC Infect Dis; 2022 Jul; 22(1):592. PubMed ID: 35787250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seasonal coronavirus protective immunity is short-lasting.
    Edridge AWD; Kaczorowska J; Hoste ACR; Bakker M; Klein M; Loens K; Jebbink MF; Matser A; Kinsella CM; Rueda P; Ieven M; Goossens H; Prins M; Sastre P; Deijs M; van der Hoek L
    Nat Med; 2020 Nov; 26(11):1691-1693. PubMed ID: 32929268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first probable case of SARS-CoV-2 reinfection in Colombia.
    Novoa W; Miller H; Mattar S; Faccini-Martínez ÁA; Rivero R; Serrano-Coll H
    Ann Clin Microbiol Antimicrob; 2021 Jan; 20(1):7. PubMed ID: 33435982
    [No Abstract]   [Full Text] [Related]  

  • 10. Are people with uncontrolled diabetes mellitus at high risk of reinfections with COVID-19?
    Pal R; Banerjee M
    Prim Care Diabetes; 2021 Feb; 15(1):18-20. PubMed ID: 32800450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity.
    Pilz S; Theiler-Schwetz V; Trummer C; Krause R; Ioannidis JPA
    Environ Res; 2022 Jun; 209():112911. PubMed ID: 35149106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Overview About the Role of Adaptive Immunity in Keeping SARS-CoV-2 Reinfections at Bay.
    Ahsan H; Sonn JK; Lee YS; Islam SU; Khalil SK
    Viral Immunol; 2021 Nov; 34(9):588-596. PubMed ID: 34101517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding protection from SARS-CoV-2 by studying reinfection.
    Overbaugh J
    Nat Med; 2020 Nov; 26(11):1680-1681. PubMed ID: 33093682
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-impact social distancing interventions to mitigate local epidemics of SARS-CoV-2.
    Jackson ML
    Microbes Infect; 2020; 22(10):611-616. PubMed ID: 32977019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia.
    Medic S; Anastassopoulou C; Lozanov-Crvenkovic Z; Dragnic N; Petrovic V; Ristic M; Pustahija T; Tsakris A; Ioannidis JPA
    JAMA Netw Open; 2023 Feb; 6(2):e2255779. PubMed ID: 36780157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Allergic reactions to COVID-19 vaccines].
    Geersing TH; Tempels-Pavlica Ž; Borgsteede SD
    Ned Tijdschr Geneeskd; 2021 Feb; 165():. PubMed ID: 33651507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could COVID-19 be contained in poor populations by herd immunity rather than by strategies designed for affluent societies or potential vaccine(s)?
    Ruppel A; Halim MI; Kikon R; Mohamed NS; Saebipour MR
    Glob Health Action; 2021 Jan; 14(1):1863129. PubMed ID: 33397199
    [No Abstract]   [Full Text] [Related]  

  • 19. Disease severity during SARS-COV-2 reinfection: a nationwide study.
    Mensah AA; Lacy J; Stowe J; Seghezzo G; Sachdeva R; Simmons R; Bukasa A; O'Boyle S; Andrews N; Ramsay M; Campbell H; Brown K
    J Infect; 2022 Apr; 84(4):542-550. PubMed ID: 35085659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covid-19 vaccines: delivering protective immunity.
    Sewell HF; Agius RM; Kendrick D; Stewart M
    BMJ; 2020 Dec; 371():m4838. PubMed ID: 33334862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.